Purple Biotech Ltd. has announced promising new data regarding its therapy NT219, a dual inhibitor targeting IRS1/2 and STAT3, for the treatment of head and neck squamous cell carcinoma (HNSCC) and ...
Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE ...
Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - ...
Vepdegestrant becomes the first FDA-approved heterobifunctional protein degrader (PROTAC) in breast cancer, targeting ER ...
Early detection and prevention of cancer can save lives, but current tools often fall short because of suboptimal accuracy and limited accessibility. The Fred Hutch Cancer Center aims to change that ...
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 19 Table 1 summarizes the eligibility criteria. Study design Quantitative (interventional or ...
Region-specific biomarkers FGFR4, FLT1, and WNT5A are linked to tumor behavior and therapeutic response in CRC. Comprehensive genomic profiling (CGP) aids in precision medicine by identifying genetic ...
World Cancer Day, marked on 4 February, is an international day dedicated to raising awareness of cancer, and to encouraging its prevention, detection and treatment. To recognise the efforts of ...
Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) from short-term survivors (<1year) OS Therapies Inc. (NYSE:OSTX) Leveraging the power ...
Treatments based on genomic profiling can significantly extend survival for patients with advanced or rare cancer, but only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results